NASDAQ:IPA

ImmunoPrecise Antibodies Stock Forecast, Price & News

$10.94
-0.80 (-6.81 %)
(As of 04/14/2021 05:20 PM ET)
Add
Compare
Today's Range
$10.83
Now: $10.94
$11.93
50-Day Range
$8.84
MA: $11.58
$14.84
52-Week Range
$2.68
Now: $10.94
$33.34
Volume69,455 shs
Average Volume115,907 shs
Market Capitalization$209.16 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IPA
CUSIPN/A
CIKN/A
Phone701 353 0022
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$209.16 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

2001st out of 2,019 stocks

Biotechnology Industry

138th out of 145 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$10.94
-0.80 (-6.81 %)
(As of 04/14/2021 05:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IPA News and Ratings via Email

Sign-up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ImmunoPrecise Antibodies (NASDAQ:IPA) Frequently Asked Questions

Is ImmunoPrecise Antibodies a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ImmunoPrecise Antibodies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPA, but not buy additional shares or sell existing shares.
View analyst ratings for ImmunoPrecise Antibodies
or view top-rated stocks.

What stocks does MarketBeat like better than ImmunoPrecise Antibodies?

Wall Street analysts have given ImmunoPrecise Antibodies a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ImmunoPrecise Antibodies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 17,000 shares, an increase of 27.8% from the March 15th total of 13,300 shares. Based on an average daily volume of 117,500 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the shares of the company are sold short.
View ImmunoPrecise Antibodies' Short Interest
.

Who are ImmunoPrecise Antibodies' key executives?

ImmunoPrecise Antibodies' management team includes the following people:
  • Dr. James S. Kuo M.B.A., M.D., Independent Chairman (Age 56)
  • Dr. Jennifer Lynne Bath Ph.D., CEO, Pres & Director
  • Ms. Lisa Helbling, Chief Financial Officer
  • Dr. Yasmina Noubia Abdiche Ph.D., Chief Scientific Officer
  • Dr. Stefan Lang, Chief Bus. Officer
  • Mr. David E. Orton, Chief Operating Officer
  • Ms. Lauren Smith, VP of Marketing and Sales

Who are some of ImmunoPrecise Antibodies' key competitors?

What is ImmunoPrecise Antibodies' stock symbol?

ImmunoPrecise Antibodies trades on the NASDAQ under the ticker symbol "IPA."

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoPrecise Antibodies' stock price today?

One share of IPA stock can currently be purchased for approximately $10.94.

How much money does ImmunoPrecise Antibodies make?

ImmunoPrecise Antibodies has a market capitalization of $209.16 million.

What is ImmunoPrecise Antibodies' official website?

The official website for ImmunoPrecise Antibodies is www.immunoprecise.com.

How can I contact ImmunoPrecise Antibodies?

The company can be reached via phone at 701 353 0022.


This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.